Naivek Submits Clinical Trial Application for Phase 1 Study of Pulmonary Fibrosis Treatment in Australia
[Asia Economy Reporter Minji Lee] On the 13th, Naibec announced that it has applied to the Australian Human Research Ethics Committee for a Phase 1 clinical trial plan of its peptide-based pulmonary fibrosis treatment.
The company stated, "After completing Phase 1 in Australia, depending on the evaluation results of pharmacokinetic characteristics, safety, tolerability, and immunogenicity identified during this clinical process, we plan to proceed to the next phase of patient-targeted clinical trials." It added, "Based on the Phase 1 results, we intend to pursue joint commercialization development and technology transfer with global pharmaceutical companies and biotech firms."
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "China's Growth Rate Expected to Fall Short of Last Year... High-Tech Industries Remain the Pillar"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
